Weihai Lotus Pharmaceuticals is a successful and rapidly growing wholly owned subsidiary of the Lotus Healthcare Group. The Company has its modern manufacturing base in Weihai City which is some one hours flying time from Beijing or Shanghai, located in the eastern coastal Province of Shandong. The facility is a modular non-sterile solid dosage form manufacturing plant designed to cope with the company's growth and with sufficient spare capacity for additional products and product forms. Sales and marketing is undertaken by the company's own growing sales force of over seventy five professional sales representatives located around the country and by selected specialized selling agents trained for that role. Sales management is headquartered in the Beijing office with additional sales offices in Weihai, Xian and Guangzhou. Weihai Lotus products are used in over 1,800 hospitals and pharmacies in 19 Provinces. Weihai Lotus manufactures and markets Galake® and Lutilium® and is licensed by the China Authorities to import and sell to licensed clients Dihydrocodeine API, Oxycodone API and subject completion of clinical trials on its finished product Morphine API. By Government license, a sustained release morphine sulphate tablet has completed comparative clinical trials and is expected to be launched in 2014. Development work on future products containing hydrocodone, oxycodone and paracetamol are in the pipeline. The company was one of the first to be certified by the CFDA as GMP compliant. Certification being valid for five years the company has since successfully undergone two further inspections. The Weihai site occupies an area of four acres and includes pharmaceutical production, office buildings, warehousing and analytical and product development laboratories with a total built up area of 13,000 m². By carefully selecting locally produced equipment and importing some of the main production equipment the right blend of cost containment, high quality and reliability has been achieved.